NEW YORK (360Dx) – Spanish firm Zenosense said today that its UK-based joint venture MIDS Medical has engaged with Future Diagnostics Solutions for assay development services.

Through its joint venture ownership in MIDS Medical, Zenosense primarily focuses on the development and commercialization of MIDS Cardiac, a point-of-care handheld device for the early detection of cardiac event biomarkers, which is used to accelerate the triage, diagnosis, treatment, and disposition of patients reporting chest pain with suspected acute myocardial infarction.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.